News

Venaxis Files Response to FDA’s Request for Additional Information

Venaxis®, Inc. today announced it has filed its response to the FDA’s Additional Information (AI) request related to the Company’s APPY1 direct de novo submission. Venaxis will provide a business update, including discussion on the APPY1 FDA submission, on Monday, December 8, 2014, at 4:30 p.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.  Read more…



Venaxis to Present at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum

Venaxis, Inc. today announced it will be presenting at the Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum being held in New York on November 20, 2014.  Read more…



Venaxis’ APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ACEP14

Venaxis, Inc. today announced results of the company’s pivotal APPY1 Test clinical trial were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14). The trial involved 29 U.S. hospital sites recruiting patients aged 2 – 20 from January 2013 through January 2014. Results were presented by Lead Principal Investigator Dr. David S. Huckins, M.D.  Read more…